SCR-A019 / Simcere - LARVOL DELTA

SCR-A019, a first-in-class biparatopic ADC targeting MSLN, with a novel topoisomerase I inhibitor demonstrates encouraging efficacy in preclinical models (AACR 2026) - "These preclinical data demonstrated SCR-A019 could be a potential first-in-class biparatopic BsADC to overcome the obstacles in antibody-based MSLN-targeting cancer therapy."

ADC • Preclinical • Oncology • Ovarian Cancer • MSLN